Zevra Therapeutics Inc Dossier - Source-backed chat

Zevra Therapeutics Inc

ZVRANASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.95

Intrinsic Value $7.90median of 5 methods · middle span $7-$14based on filings through 30 Jun 2026

Market Price $10.97Price as of 30 Sep 2026

OvervaluedIntrinsic value is 28% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $651.4M

Enterprise Value $506.1M

Shares Outstanding 62M diluted

Moat Rating Wide

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Zevra Therapeutics has successfully transitioned from a specialty CNS licensing company into a focused, commercial-stage rare disease player. This transformation is anchored by the landmark FDA approval of MIPLYFFA (arimoclomol) in September 2024 for Niemann-Pick disease type C (NPC). MIPLYFFA has demonstrated rapid commercial uptake, generating $87.4 million in net revenue in 2025 and continuing its strong trajectory with $24.6 million in Q1 2026. The strategic divestiture of the non-core SDX portfolio in March 2026 for $50 million cash has eliminated litigation overhangs, enabled the full prepayment of outstanding debt, and left Zevra with a robust, debt-free balance sheet holding $236.8 million in cash. With a highly concentrated rare disease focus, stable commercial execution, and an impending regulatory catalyst in Europe (EMA review of arimoclomol), Zevra represents a compelling, de-risked investment opportunity with significant valuation upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$25.00

High · most bullish analyst$35.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

MIPLYFFA's U.S. commercial growth plateaus as patient enrollment slows and competitive pressures emerge from newly approved therapies (such as Intrabio's Aqneursa). The EMA issues a negative opinion or requests additional clinical trials for arimoclomol, delaying or blocking European commercialization and impacting EAP reimbursement revenues. Operating expenses rise unexpectedly due to manufacturing scale-up challenges or clinical trial delays for celiprolol, accelerating cash burn and shortening the projected cash runway.

Base CaseCentral scenario

MIPLYFFA continues its steady commercial expansion in the U.S., maintaining stable market access at approximately 69% of covered lives and steadily adding new patient enrollments. The EMA grants marketing authorization for arimoclomol in late 2026 or early 2027, allowing Zevra to transition its European Expanded Access Program (EAP) patients to commercial reimbursed supply. Operating expenses remain disciplined following the relocation of headquarters to Boston and the scale-back of the low-performing OLPRUVA franchise. The company leverages its $236.8 million cash cushion to comfortably fund operations past 2027 while advancing celiprolol in Phase 3.

Bull CaseUpside scenario

Strong commercial execution of MIPLYFFA in the U.S. ultra-rare NPC market, combined with a robust cash position of $236.8 million and no long-term debt, provides a solid foundation for growth. Additional upside is driven by the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome (vEDS), which targets a high-unmet-need market with no FDA-approved competition.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial foundation with MIPLYFFA, the first FDA-approved therapy specifically indicated for Niemann-Pick disease type C (NPC).
Robust, debt-free balance sheet with $236.8 million in cash, cash equivalents, and investments as of March 31, 2026, providing a long operational runway.
Sharpened strategic focus on rare diseases following the successful $50 million divestiture of the non-core SDX portfolio in March 2026.
Significant near-term regulatory catalyst with the ongoing European Medicines Agency (EMA) review of arimoclomol.

Key Investment Risks

High concentration of revenue on a single commercial product (MIPLYFFA), making the company vulnerable to any commercial or supply chain disruptions.
Regulatory risk associated with the EMA review of arimoclomol, where a negative outcome would limit international expansion.
Commercial execution risk in a highly specialized ultra-rare disease market with a small total addressable patient population.
Potential clinical development and regulatory hurdles for pipeline candidates, specifically celiprolol for vEDS.

Thesis Invalidation Triggers

A regulatory rejection (Refusal to Approve or negative CHMP opinion) by the EMA for arimoclomol in Europe.
A sharp decline in MIPLYFFA new patient enrollments or a significant reduction in insurance coverage/reimbursement rates in the U.S.
Unexpected clinical trial failures or safety signals in the Phase 3 development of celiprolol.
Rapid cash depletion due to undisciplined operational spending or failure to manage commercialization costs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.